Sign in →

Test Code LAB1231814 Bordetella pertussis Antibody, IgG, Serum

Important Note

Mayo code is BORDG

Useful For

Diagnosis of recent infection with Bordetella pertussis in patients with symptoms consistent with whooping cough for 2 or more weeks

 

This test should not be used in neonates, young infants or in children between the ages of 4 to 7 years as the routine childhood vaccine schedule may interfere with result interpretation.

 

This test should not be used as a test of cure, to monitor response to treatment, or to determine vaccine status.

Reporting Name

B. pertussis Ab, IgG, S

Specimen Type

Serum


Ordering Guidance


This test should be ordered in patients with 2 or more weeks of symptoms consistent with whooping cough. Nucleic acid amplification testing for Bordetella pertussis should be used in patients who have been symptomatic less than 2 weeks; order BPRPV / Bordetella pertussis and Bordetella parapertussis, Molecular Detection, PCR, Varies.



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL Serum

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

Serum: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 30 days
  Frozen  30 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-inactivated specimen Reject

Reference Values

≥100 IU/mL (Positive)

40-<100 IU/mL (Borderline)

<40 IU/mL (Negative)

Reference values apply to all ages.

Supportive Data

Accuracy:

A total of 108 previously characterized serum samples (originally tested by Focus Diagnostics Inc.) were evaluated by the EuroImmun antipertussis toxin (PT) IgG EIA (enzyme innumoassay) and the results are indicated below.

 

Comparison of the EuroImmun and Focus Diagnostics Bordetella pertussis PT EIAs

           

Focus Diagnostics PT EIA

Positive

Negative

EuroImmun PT EIA

Positive

18

0

Negative

0

77

Borderline(a)

8(b)

5(c)

 

 

 

 

 

 

 

 

 

(a) Testing of a convalescent sample is recommended. Samples not included in positive and negative agreement calculations below.

(b) All 8 samples had low positive values by the Focus assay.

(c) All 5 samples were near the lower end of the borderline range for the EuroImmun ELISA.

 

Positive Agreement: 100% (18/18); 95% CI: 79.3%-100%

Negative Agreement: 100% (77/77); 95% CI: 94.3%-100%

Method Description

The antipertussis toxin (PT) IgG enzyme-linked immunosorbent assay (ELISA) test is a quantitative assay. Microtiter wells are coated with PT from Bordetella pertussis and diluted patient samples, calibrators, and controls are incubated in the wells. If present, antibodies to B pertussis will bind to the antigen. After wells are washed, enzyme-labeled antihuman IgG is added, and wells are incubated a second time. After incubation, wells are washed and a tetramethylbenzidine chromogen/substrate solution is added and wells are incubated. Stop solution is added to stop the reaction. Wells are read using a microplate reader with 450/620 nm wavelength. Calibrator values are plotted to make a point-to-point standard curve. Sample antibody concentrations are determined using the standard curve.(Package insert: Anti-Bordetella pertussis toxin ELISA (IgG) Test Instructions. EUROIMMUN US; 02/2025)

Day(s) Performed

Thursday

Report Available

Same day/1 to 7 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

86615

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BORDG B. pertussis Ab, IgG, S 42330-1

 

Result ID Test Result Name Result LOINC Value
BIGG B. pertussis IgG 29659-0
DEXBG B.pertussis Value 42330-1

Forms

If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.